Chemotherapy News and Research

Latest Chemotherapy News and Research

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Individuals with hair loss can benefit from Sequencing technique

Hair loss remains an important distressing side effect for certain patients and individuals and although there are certainly more critical health issues there is no doubt that loss of hair is a stressful experience for men and women.

2 Jun 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

Women with ovarian cancer could benefit from new targeted testing

Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.

1 Jun 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Two of Almac's main research projects have been selected for presentation at the 2011 ASCO meeting. Both of these studies are based on Almac's approach of profiling large clinical datasets and analysing the data for molecular subgroups that can aid in improved diagnosis of cancer by identifying molecular subtypes and by identifying molecular subgroups which are of clinical and therapeutic relevance.

31 May 2011

Ten changes medical oncologists can do to flatten costs, improve care

The cost of cancer care is threatening to bankrupt our healthcare system. New drugs are prolonging life, but at staggering costs. This coupled with aging baby boomers and an increasing population mean the U.S. will spend $173 billion annually on cancer care by the year 2020. This trend is not sustainable; however, there are evidence-based ways to maintain or improve the quality of care while saving money for the new therapies being discovered every day.

27 May 2011

Innovations in diagnosis and treatment for esophageal cancer

In recent years, the number of cases of adenocarcinoma of the esophagus (or gullet) has been on the rise. At the same time, however, new ways of treatment are improving the outlook for patients. In the current issue of Deutsches Ärzteblatt International, Angelika Behrens and her working group report on innovations in diagnosis and treatment.

27 May 2011

Abiraterone acetate effective for men with advanced prostate cancer

A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months.

27 May 2011

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

Nurses can play vital role in increasing patients' adherence to cancer-fighting medication

As the use of oral chemotherapy continues to rise, researchers from Michigan State University have discovered many patients fail to properly take the cancer-fighting medication, a significant clinical problem that can result in complications and premature death.

26 May 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Individuals with hair loss can benefit from Sequencing technique

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Lymphoma vaccine extends disease-free survival by 14 months

Women with ovarian cancer could benefit from new targeted testing

YM announces updates on nimotuzumab clinical development program

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Ten changes medical oncologists can do to flatten costs, improve care

Innovations in diagnosis and treatment for esophageal cancer

Abiraterone acetate effective for men with advanced prostate cancer

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Nurses can play vital role in increasing patients' adherence to cancer-fighting medication

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in